Black Diamond Therapeutics, Inc. (BDTX)


Stock Price Forecast

April 17, 2024


Forecasted Returns

7 Days Predict

30 Days Predict

90 Days Predict


Forecasted Market-Excess Returns

7 Days Predict

30 Days Predict

90 Days Predict

Loading Black Diamond Therapeutics, Inc. chart...

About the Company

We do not have any company description for Black Diamond Therapeutics, Inc. at the moment.

Exchange

Nasdaq

$M

Total Revenue

80

Employees

$294M

Market Capitalization

-2.88

Price/Earning ratio

Fundamental Data and Insider Transactions (Quarterly data) Full Screen

Loading the fundamentals chart...

Latest $BDTX News

Black Diamond Therapeutics (BDTX) Price Target Increased by 20.75% to 13.06

1d ago, source: Fintel on MSN

The average one-year price target for Black Diamond Therapeutics (NasdaqGS:BDTX) has been revised to 13.06 / share. This is ...

BDTX Black Diamond Therapeutics, Inc.

26d ago, source: Seeking Alpha

Black Diamond Therapeutics, Inc., a clinical-stage oncology medicine company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors.

Black Diamond Therapeutics Announces Changes to Board of Directors

6d ago, source:

Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancers, today announced ...

Black Diamond Therapeutics Inc (BDTX) Stock: A Guide to the Market Trend

6d ago, source: newsheater

To wrap up, the performance of Black Diamond Therapeutics Inc (BDTX) has been better in recent times. The stock has received a mixed of “buy” and “hold” ratings from analysts. It is worth mentioning ...

Black Diamond Therapeutics to Participate in Upcoming Investor Conferences

15d ago, source: Yahoo Finance

CAMBRIDGE, Mass. and NEW YORK, April 03, 2024 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target ...

Black Diamond Therapeutics Inc.

21d ago, source: Wall Street Journal

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Black Diamond Therapeutics Inc Ordinary Shares

6d ago, source: Morningstar

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Black Diamond Therapeutics Inc.

5d ago, source: Barron's

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...

Black Diamond Therapeutics Inc.

26d ago, source: Wall Street Journal

1 Day BDTX 6.10% DJIA -0.77% Russell 2K -1.27% Health Care/Life Sciences 0.09% ...

Latest Neutral (free) Forecasts

STRONG BUY BUY NEUTRAL SELL STRONG SELL ALL

Loading the latest forecasts...

My Portfolio

Loading your portfolio...